SOURCE: Faruqi & Faruqi, LLP

Faruqi & Faruqi, LLP

February 08, 2016 15:42 ET

Shareholder Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Tetraphase Pharmaceuticals, Inc. to Contact the Firm Before Lead Plaintiff Deadline

NEW YORK, NY--(Marketwired - February 08, 2016) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Tetraphase Pharmaceuticals, Inc. ("Tetraphase" or the "Company") (NASDAQ: TTPH) of the March 28, 2016 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers.

The lawsuit has been filed in the U.S. District Court for the District of Massachusetts on behalf of all those who purchased Tetraphase securities between March 5, 2015 and September 8, 2015 (the "Class Period"). The case, Harrington v. Tetraphase Pharmaceuticals Inc. et al, No. 1:16-cv-10133 (D. Mass. Jan 28, 2016) was filed on January 28, 2016, and has been assigned to Judge Leo T. Sorokin.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by misrepresenting the capacity for clinical approval of Eravacycline, an intravenous (IV) to oral transition therapy for the treatment of complicated urinary tract infections, by both the U.S. Food and Drug Administration ("FDA") and the European Medicines Agency ("EMA").

Specifically, on September 8, 2015, Tetraphase announced negative results of the pivotal portion of Eravacycline during the IGNITE2 phase 3 clinical trial. The Company disclosed that Eravacycline had failed to achieve its primary endpoint of statistical non-inferiority compared to Levofloxacin under the guidelines established by both the FDA and EMA.

After this announcement, Tetraphase's share price fell from $44.78 per share on September 8, 2015 to a closing price of $8.36 on September 10, 2015-a $36.42 or a 81.3% drop.

Request more information now by clicking here: www.faruqilaw.com/TTPH. There is no cost or obligation to you.

Take Action

If you invested in Tetraphase securities between March 5, 2015 and September 8, 2015 and would like to discuss your legal rights, visit www.faruqilaw.com/TTPH. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com. Faruqi & Faruqi, LLP also encourages anyone with information regarding Tetraphase's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class that is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. 

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

Contact Information

  • FARUQI & FARUQI, LLP
    685 Third Avenue, 26th Floor
    New York, NY 10017
    Attn: Richard Gonnello, Esq.
    Email contact

    Telephone: (877) 247-4292 or (212) 983-9330